Home/Filings/4/0000891839-19-000038
4//SEC Filing

Vaccinex (Rochester), L.L.C. 4

Accession 0000891839-19-000038

CIK 0001205922other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 4:30 PM ET

Size

14.3 KB

Accession

0000891839-19-000038

Insider Transaction Report

Form 4
Period: 2019-03-14
Transactions
  • Purchase

    Common Stock

    2019-03-14$4.00/sh+1,000$4,0004,789,469 total(indirect: By FCMI Parent Co.)
  • Purchase

    Common Stock

    2019-03-15$3.96/sh+1,000$3,9604,790,469 total(indirect: By FCMI Parent Co.)
Holdings
  • Common Stock

    439,555
  • Common Stock

    (indirect: By Global Macro Hedge Fund Ltd.)
    583,333
  • Option (Right to Acquire)

    (indirect: By FCMI Financial Corporation)
    Common Stock (967,983 underlying)
    9,679,833
  • Common Stock

    (indirect: By Trust)
    37,633
  • Option (Right to Acquire)

    (indirect: By FCMI Parent Co.)
    Common Stock (1,180,051 underlying)
    21,475,000
FRIEDBERG ALBERT
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2019-03-14$4.00/sh+1,000$4,0004,789,469 total(indirect: By FCMI Parent Co.)
  • Purchase

    Common Stock

    2019-03-15$3.96/sh+1,000$3,9604,790,469 total(indirect: By FCMI Parent Co.)
Holdings
  • Common Stock

    (indirect: By Trust)
    37,633
  • Common Stock

    439,555
  • Option (Right to Acquire)

    (indirect: By FCMI Parent Co.)
    Common Stock (1,180,051 underlying)
    21,475,000
  • Common Stock

    (indirect: By Global Macro Hedge Fund Ltd.)
    583,333
  • Option (Right to Acquire)

    (indirect: By FCMI Financial Corporation)
    Common Stock (967,983 underlying)
    9,679,833
Footnotes (7)
  • [F1]Mr. Friedberg is the majority owner of Pan Atlantic Bank & Trust Ltd. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  • [F2]Mr. Friedberg possesses voting and dispositive power over the reported securities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  • [F3]The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by FCMI Parent Co. on January 23, 2019.
  • [F4]Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  • [F5]Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, FCMI Parent Co. entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date.
  • [F6]Limited partnership units of Vaccinex Products, LP, which are exchangeable into shares of Common Stock on a 1-for-10 basis at the holder's option.
  • [F7]FCMI Financial Corp. is a wholly-owned subsidiary of FCMI Parent Co. Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.

Issuer

VACCINEX, INC.

CIK 0001205922

Entity typeother
IncorporatedGA

Related Parties

1
  • filerCIK 0001747866

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 4:30 PM ET
Size
14.3 KB